The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global cell therapy market size reached US$ 9.17 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 27.05 Billion by 2027, exhibiting a growth rate (CAGR) of 18.60% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Cell therapy (CT) is the transplantation of human cells to replace or repair damaged tissues and cells. It comprises hematopoietic stem cells (HSC), skeletal muscle and mesenchymal stem cells, lymphocytes, and dendritic and pancreatic islet cells. It improves the immune system of the body to fight cancer cells. Apart from this, cell therapy assists in treating various conditions, such as autoimmune and infectious diseases, urinary problems, damaged cartilage in joints, spinal cord injuries, a weakened immune system, and neurological disorders. At present, it is used to manufacture regenerative medicines for developing and applying new treatments to heal tissues and organs and restore functions lost due to aging, disease, and damage.
At present, there is a rise in the prevalence of various diseases, such as cancer and cardiac abnormalities, across the globe. This, along with the growing number of clinical studies for cell-based therapies, represents one of the key factors driving the market. Besides this, governing agencies of several countries are promoting clinical trials around the world, which is contributing to the growth of the market. In addition, key market players are extensively investing in research and development (R&D) activities to introduce skin rejuvenation and tendon regeneration therapies. They are also focusing on developing direct cell reprogramming to replace lost neuronal tissues due to neurodegeneration or neurotrauma. Moreover, there is an increase in the development of advanced genomic therapy techniques to treat various diseases, such as cystic fibrosis, heart disease, diabetes, hemophilia, and acquired immune deficiency syndrome (AIDS). This, coupled with the burgeoning healthcare industry, is propelling the growth of the market. Apart from this, the rising demand for regenerative medicines to replace tissue or organs damaged by diseases, traumas, or congenital issues is bolstering the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global cell therapy market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on cell type, therapy type, therapeutic area and end user.
Breakup by Cell Type:
Breakup by Therapy Type:
Breakup by Therapeutic Area:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AlloSource, Anterogen Co. Ltd., Cells for Cells, Holostem Terapie Avanzate S.r.l., JCR Pharmaceuticals, Kolon TissueGene Inc., MEDIPOST, Mesoblast Limited, NuVasive, Stemedica Cell Technologies Inc., Stempeutics Research Pvt. Ltd and Vericel Corporation.
|Base Year of the Analysis||2021|
|Segment Coverage||Cell Type, Therapy Type, Therapeutic Area, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||AlloSource, Anterogen Co. Ltd., Cells for Cells, Holostem Terapie Avanzate S.r.l., JCR Pharmaceuticals, Kolon TissueGene Inc., MEDIPOST, Mesoblast Limited, NuVasive, Stemedica Cell Technologies Inc., Stempeutics Research Pvt. Ltd and Vericel Corporation.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at